uranium workers, 116–117, 119, 121, 128, 134–135, 138, 149

vaccines, 302, 311–312

Agency for Toxic Substances and Disease Registry (ATSDR), 94, 99, 106

Agent Orange, 29, 334

AIDS, 310, 342, 345

Air Force Technical Applications Center (AFTAC), 173

Alcohol abuse, 45, 49

Alkaline phosphatase (ALP), 150

Aluminum hydroxide adjuvant, 274, 276

Alzheimer’s disease, 213, 227

American College of Rheumatology, 355

American Psychiatric Association, 345, 346, 360

Ammunition

depleted uranium, 5, 6, 92–93, 98, 326

sarin, 172

see also Armor

Animal studies, 2, 71–72, 80, 99, 351

anthrax vaccines, 21, 277–280, 330

botulinum toxoid vaccines, 21, 288, 289–291, 330

cyclosarin, 186–187

depleted uranium, 99, 100–101, 151, 327

fatigue, 72, 351

multiple vaccinations, 297–299

pain, 72

pyridostigmine bromide (PB), 209, 210–211, 213, 214, 215, 218–219, 220

sarin, 10, 175–176, 177, 178–187, 288

squalene, 308–309

uranium, 21, 96, 97–98, 99–106, 107, 151, 159, 327

vaccines, 271, 272, 277–280, 288, 289–291, 297–299, 308–309, 330

see also Primate equilibrium platform

Anthrax Vaccine Expert Committee, 284

Anthrax Vaccine Immunization Program, 15, 274, 330

Anthrax vaccines, vii, 1, 2, 4, 14, 15–16, 19, 21, 28, 268, 272, 274–287, 306, 312–313, 330, 335

acute effects, 15, 16, 19, 277–287 (passim), 304, 313

animal studies, 21, 277–280, 330

antibodies, 279, 285, 306

antigens, general, 15, 54, 274–277 (passim), 279–280

cardiovascular system, 278, 280

cellular processes, general, 272, 276, 301, 302

chronic effects, 19, 287, 312–313

clinical studies, 15–16, 19, 282–283, 284–287, 334

dermal effects, 15, 16, 272(n.3), 279, 281–287 (passim)

dose factors, 274–275, 278, 285

edema, 15, 275, 276, 277, 278, 283, 284

exposure routes, 272(n.3), 275

dermal, 272(n.3), 282, 283

ingestion, 272(n.3)

inhalation, 272(n.3), 276–277, 282, 283

injection delivery, 15, 279–286 (passim), 297

FDA, 14, 267, 274, 283–284, 287, 313

fever, 16, 277–278, 282, 284, 285, 287

gastrointestinal effects, 272(n.3), 285

gender factors, 286

genetic effects, 280

headaches, 281, 284, 285

historical perspectives, 272, 274, 281, 283–284, 287

hospitalization following administration, 284, 286

immune system pathologies, 279, 284, 285, 290–292, 306

inflammation, 278, 281, 284, 286, 287, 297

live attenuated spore vaccines, 274, 276, 277–279, 281, 297

lymphatic system, 278

mental disorders, 284

mortality, 277, 278

multiple vaccinations, 301, 304

nausea and vomiting, 284, 285

neuromuscular effects, 281, 284, 285, 286

neuropathy, general, 285

number of vaccinations given, 15, 267, 274, 284

pain, 281–282, 284, 285, 286

protective antigen vaccines, 274, 276–277, 279–280, 281, 282

rashes, 284, 285

reproductive system effects, 226



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement